IGM Biosciences (STU:1K0) Total Stockholders Equity : €148.35 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is IGM Biosciences Total Stockholders Equity?

IGM Biosciences's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €148.35 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. IGM Biosciences's Book Value per Share for the quarter that ended in Mar. 2024 was €2.52. The ratio of a company's debt over equity can be used to measure how leveraged this company is. IGM Biosciences's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.25.

IGM Biosciences Total Stockholders Equity Historical Data

The historical data trend for IGM Biosciences's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IGM Biosciences Total Stockholders Equity Chart

IGM Biosciences Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

216.21

313.85

216.74

271.18

186.37

IGM Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															223.63	238.69	237.87	186.37	148.35

IGM Biosciences (STU:1K0) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

IGM Biosciences's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(148.353	-	0)	/	58.9509
	=	2.52

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

IGM Biosciences's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.098	+	31.556)	/	148.353
	=	0.25

IGM Biosciences Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of IGM Biosciences's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

IGM Biosciences (STU:1K0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IGM Biosciences Inc (STU:1K0) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

IGMS:USA

Address

325 East Middlefield Road, Mountain View, CA, USA, 94043

Website

https://www.igmbio.com

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 protein, IGM-8444, a combination with a chemotherapeutic agent such as irinotecan, gemcitabine, or venetoclax, and IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

IGM Biosciences (STU:1K0) Headlines

No Headlines